Vivitrol Overview: Understanding Naltrexone Treatment for Addiction Recovery
Vivitrol provides a monthly injectable treatment option for those committed to overcoming alcohol or opioid addiction. What is Vivitrol? It is a long-acting formulation of naltrexone, an opioid antagonist that blocks opioid receptors in your brain. What does Vivitrol do? It reduces cravings and prevents the euphoric effects of alcohol and opioids, supporting your recovery experience. Vivitrol requires you to be opioid-free for 7 to 10 days before starting treatment, so proper preparation is essential. This guide covers how Vivitrol works, administration requirements, side effects, and important safety considerations.
What Is Vivitrol and How Does It Work
Naltrexone serves as the active pharmaceutical ingredient in Vivitrol, marketed as an extended-release injectable suspension designed to treat addiction. The medication received FDA approval in 2006 to treat alcohol dependence and gained approval in 2010 to prevent relapse to opioid dependence.
Naltrexone as an Opioid Antagonist
Naltrexone functions as a semi-synthetic opioid with competitive antagonist activity at mu opioid receptors. As a pure opioid receptor antagonist, it binds at the mu opioid receptors in your central nervous system and blocks these sites where opioids would attach. After a standard oral dose of 50 mg naltrexone, brain-imaging studies show that 95% of cerebral mu opioid receptors become occupied.
Naltrexone demonstrates highest affinity for the mu opioid receptor. It also acts as a weaker antagonist at the kappa and delta opioid receptors. This competitive binding mechanism means naltrexone occupies receptor sites without activating them and prevents other substances from producing their effects. The medication has little to no opioid agonist activity. It will not produce opioid-like effects or cause mental or physical dependence.
Vivitrol exists as a noncontrolled substance with no known abuse or diversion potential. This makes it especially appealing in clinical and criminal justice settings. The medication is not aversive therapy and does not cause unpleasant disulfiram-like reactions as a result of opioid use or ethanol ingestion.
Monthly Injectable Formulation
Vivitrol contains naltrexone embedded in a microsphere matrix composed of biodegradable polyglycolide, the same material used in dissolvable sutures and other extended-release pharmaceuticals. This formulation delivers 380 mg of naltrexone mixed with a diluent as a deep intramuscular gluteal injection. The microspheres are administered every 4 weeks or once a month. You alternate buttocks for each injection.
The intramuscular injection of extended-release naltrexone avoids first-pass hepatic metabolism. The total monthly dose administered is considerably less for the extended-release form (380 mg) compared with oral naltrexone (1,500 mg). Plasma concentration peaks approximately 2 hours after injection, followed by a second peak approximately 2 to 3 days later. Plasma concentrations slowly decline beginning approximately 7 days after dosing while maintaining therapeutic naltrexone blood levels over 4 weeks.
Blocking Effects on Opioid Receptors
Naltrexone works by producing a complete but reversible block of opioid effects. These include physical dependence, respiratory depression, miosis (pinpoint pupils), analgesia (pain relief), euphoria, drug craving and tolerance. The medication blocks both exogenous opioids (heroin, morphine, codeine) and endogenous opioid peptides your body produces.
Naltrexone blocks the effects of endogenous opiates like endorphins for alcohol use disorder. This makes alcohol ingestion less pleasurable. This mechanism reduces alcohol cravings and the amount consumed. Vivitrol blocks the effects of exogenous opioids for approximately 28 days after administration.
The blockade produced by naltrexone is surmountable through competitive binding at opioid receptors. But attempting to overcome full naltrexone blockade by administering large doses of opioids may result in non-opioid receptor-mediated symptoms such as histamine release or lead to life-threatening opioid intoxication.
Vivitrol for Alcohol and Opioid Use Disorders
Extended-release naltrexone gained FDA approval for treating alcohol dependence in 2006, followed by approval for opioid use disorder treatment. These approvals position Vivitrol as a treatment option for two distinct but often overlapping addiction challenges.
Treatment for Alcohol Dependence
Naltrexone has been used for decades to treat alcohol use disorder and has established a long track record in clinical settings. The medication binds to endorphin receptors in your body and blocks the effects and feelings of alcohol when you receive Vivitrol treatment for alcohol dependence. This blocking action reduces alcohol cravings and the amount consumed.
Clinical trials demonstrate measurable outcomes. Patients receiving Vivitrol 380 mg with counseling experienced 25% fewer heavy drinking days per month compared to those receiving placebo with counseling in a 24-week placebo-controlled study. Heavy drinking was defined as five or more standard drinks per day for men and four or more for women.
Subset analysis reveals even stronger results for specific patient populations. Those treated with Vivitrol showed greater reductions in both drinking days and heavy drinking days compared to placebo-treated patients among patients who achieved seven consecutive days of abstinence before their first injection. Real-life research indicates that patients leaving treatment on Vivitrol are 26% more likely to report abstaining from alcohol or non-prescribed drugs for at least 30 days one year after treatment. Outcomes improve when you continue Vivitrol for at least three months.
Treatment for Opioid Addiction
Vivitrol represents the newest FDA-approved medication for treating opioid use disorder, though its mechanism is different from methadone and buprenorphine. The medication blocks the euphoric and sedative effects of opioids such as heroin, morphine, and codeine while reducing and suppressing opioid cravings. Studies show naltrexone works at treating opioid use disorder.
But treatment retention presents challenges. People prescribed naltrexone are more likely to drop out of treatment in the first 30 days compared to those taking buprenorphine. On top of that, because naltrexone is not an opioid, you lose your opioid tolerance while taking it. This increases risk of harm in the event of return to illicit use. The FDA released a warning in 2019 about increased risk of overdose after cessation of naltrexone treatment and noted this risk may exist while someone remains in treatment. Methadone and buprenorphine have been proven to prevent opioid overdose. Evidence is growing that naltrexone increases the risk of overdose among those who take it to treat opioid use disorder.
Medication-Assisted Treatment Approach
Medication for Addiction Treatment combines medications with psychosocial therapies and supports to provide a whole-person approach to treating substance use disorders. Vivitrol must be used with other alcohol or drug recovery programs such as counseling to work. This detailed approach addresses both the biological and psychological aspects of addiction.
The prescribed medications operate to normalize brain chemistry, block the euphoric effects of alcohol and opioids, and relieve physiological cravings. They normalize body functions without the negative effects of the abused drug. Research shows that a combination of medication and counseling can treat substance use disorders and help sustain recovery. Any clinician licensed to prescribe medication can prescribe naltrexone, and special training is not required.
Administration and Dosing Requirements
Proper administration of Vivitrol requires careful attention to dosing protocols and patient preparation to ensure both safety and treatment efficacy.
380mg Intramuscular Injection Schedule
The recommended dose of Vivitrol is 380 mg delivered intramuscularly as a deep gluteal injection every 4 weeks or once a month. You receive this injection in the upper outer quadrant of your buttock, and the injection site alternates between right and left buttocks for each subsequent injection. The medication comes in single-use cartons containing one 380 mg vial of microspheres, diluent for suspension, a prepackaged syringe, and customized administration needles.
Healthcare providers select the appropriate needle length based on your body composition. Patients with larger amounts of subcutaneous tissue overlying the gluteal muscle may need the supplied 2-inch needle to ensure the medication reaches the intramuscular mass. Very lean patients may require the 1.5-inch needle to prevent the needle from contacting the periosteum.
Opioid-Free Period Before Starting Treatment
An opioid-free duration of a minimum of 7-10 days is recommended before you start Vivitrol to avoid precipitation of opioid withdrawal that may be severe enough to require hospitalization. This waiting period varies based on the type of opioid you used before.
Short-acting opioids such as heroin, oxycodone, and hydrocodone require a minimum 7-10 day opioid-free period before you start Vivitrol. Buprenorphine and Sublocade just need extended waiting periods of weeks to months due to prolonged half-life, with Sublocade having a 43-60 day half-life. Patients who stop methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks after discontinuation.
Your healthcare provider may conduct a naloxone challenge test to verify readiness. This involves administering low-dose naloxone and monitoring for withdrawal symptoms. The test stops if withdrawal signs occur, and you receive symptomatic treatment. Some providers start with a 25 mg oral naltrexone test dose and may proceed to the full Vivitrol injection if no withdrawal signs occur.
Healthcare Provider Administration Process
Vivitrol must be prepared and administered by a healthcare provider using aseptic technique. You cannot attempt to self-inject, as serious reactions requiring hospitalization might happen. The provider suspends the medication only in the supplied diluent and administers it with one of the provided needles from the carton.
You recline face down with your gluteal muscle relaxed during administration. The provider aspirates for blood before injection; if blood aspirates or the needle clogs, they abort the injection at that site and select another location.
What to Expect During Treatment
You undergo a 20-minute observation period following your first injection. You complete the Subjective Opiate Withdrawal Scale during this time while your clinician completes the Clinical Opiate Withdrawal Scale.
Schedule another appointment as soon as possible if you miss your appointment for your injection. The injection lasts for a month and cannot be removed from your body after it is administered. Tell the treating healthcare provider that you receive Vivitrol injections whenever you need medical treatment and mention when you got your last dose. You should carry written information at all times to alert healthcare providers about your treatment so they can treat you in an emergency.
Side Effects and Safety Considerations
Vivitrol offers therapeutic benefits, but you should understand what adverse effects mean and the monitoring to be done during treatment.
Common Side Effects
Most patients tolerate Vivitrol reasonably well, though certain adverse effects occur with notable frequency. Nausea, vomiting, injection site reactions (such as induration, pruritus, nodules and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, and decreased appetite appear in at least 5% of patients at twice the rate of placebo when treating alcohol dependence. Opioid-dependent patients experience hepatic enzyme abnormalities, injection site pain, nasopharyngitis, insomnia, and toothache most often. Other common effects include headache, painful joints and trouble sleeping.
Injection Site Reactions
Injection site complications range from mild to severe and can appear more than 10 days after medication administration, though reactions occur within 1 to 3 days of injection. The FDA issued an alert after receiving 196 reports of injection site reactions such as cellulitis, induration, hematoma, abscess, sterile abscess, and necrosis, with 16 cases requiring surgical intervention. This happened back in 2008. One patient developed enlarging induration after 4 weeks that progressed to necrotic tissue requiring surgical excision. You should monitor pain, swelling, tenderness, induration, bruising, pruritus, or redness at the injection site. Contact your healthcare provider if reactions worsen or persist beyond two weeks.
Liver Function Monitoring
Naltrexone possesses the capacity to cause hepatocellular injury when administered, though Vivitrol does not appear hepatotoxic at recommended doses. All the same, you should watch symptoms of liver problems such as dark urine, general tiredness and weakness, light-colored stools, nausea and vomiting, upper right stomach pain, and yellowing of your skin or eyes. Your healthcare provider may monitor liver function tests at baseline and during treatment.
Depression and Suicidal Thoughts
Depression-related events require careful monitoring. Suicidal events (ideation, attempts, completed suicides) occurred more often with Vivitrol than placebo (1% vs 0) when controlled trials of alcohol-dependent adults were conducted. Depressed mood was reported by 10% of patients treated with Vivitrol 380 mg compared to 5% receiving placebo injections. Two completed suicides occurred, both in Vivitrol-treated patients. Your family members and caregivers should monitor you for emerging depression or suicidality symptoms.
Eosinophilic Pneumonia Risk
Some patients develop eosinophilic pneumonia, a type caused by allergic reaction that may require hospitalization. This rare but serious condition can lead to acute respiratory distress syndrome. Contact your healthcare provider right away if you develop progressive dyspnea, hypoxemia, chest pain, dry cough, fever, skin rash, or trouble breathing.
Important Warnings and Precautions
Certain medical conditions and circumstances make Vivitrol unsafe or inappropriate for use.
Who Should Not Use Vivitrol
Vivitrol is contraindicated in patients receiving opioid analgesics, those with current physiologic opioid dependence, patients in acute opioid withdrawal, individuals who have failed the naloxone challenge test or have a positive urine screen for opioids, and patients who have expressed hypersensitivity to naltrexone, polylactide-co-glycolide, carboxymethylcellulose, or any diluent components.
Risk of Opioid Overdose After Treatment
Opioid tolerance reduces from pretreatment baseline after Vivitrol treatment. This makes you vulnerable to fatal overdose at the end of a dosing interval, after missing a dose, or after you stop treatment. Patients who used opioids during these vulnerable periods have experienced opioid overdose with fatal outcomes. People on Vivitrol are more than twice as likely to overdose compared to those on buprenorphine.
Pain Management While on Vivitrol
Emergency situations that require pain management call for regional analgesia or non-opioid analgesics. Opioid therapy may become necessary and must be administered by healthcare providers trained in anesthetic drugs and respiratory management. The setting must be equipped and staffed for cardiopulmonary resuscitation.
Carrying Medical Identification
You should carry written information at all times to alert healthcare providers that you are taking Vivitrol. This card helps medical personnel provide appropriate care during emergencies when opioid-containing medicines might otherwise be prescribed.
Is Vivitrol Covered by Insurance
Conclusion
Vivitrol offers a viable monthly treatment option for alcohol and opioid addiction recovery. This extended-release naltrexone formulation blocks opioid receptors and reduces cravings. It prevents euphoric effects associated with substance use. The medication demonstrates effectiveness when combined with counseling and psychosocial support. This creates a complete medication-assisted treatment approach.
Your success with Vivitrol depends on careful preparation, especially when you have the required opioid-free period before starting treatment. Ongoing monitoring for side effects and adherence to your monthly injection schedule are critical. Work with your healthcare provider to determine whether Vivitrol lines up with your recovery goals and medical circumstances.